Recently published

Jurisdiction / Region

  • Loading...

More information


CMS Worldwide

Selected jurisdiction


Latest news

Press contact





404 - Page not found

404 - Page not found

Unfortunately, we can’t seem to find the page you’re looking for.

Error code: 404



Next Events


CMS on LinkedIn

Follow us

Picture of Carina Healy

Carina Healy


CMS Cameron McKenna Nabarro Olswang LLP
1 West Regent Street
G2 1AP
United Kingdom
Languages English

Carina Healy is partner in our Technology team with over 20 years experience advising on commercial and IP related transactions. She specialises in lifesciences and acts for a range of biotech, speciality pharma, medical device and medical technology companies. She also has a focus on academic institutions, having worked closely with long standing clients University of Glasgow, Dundee University, and University College London for many years.

Carina regularly advises her clients on large, complex and strategically important IP and commercial arrangements, including in and out licensing, clinical trials, strategic alliances, technology development collaborations, and manufacturing, supply and distribution agreements.  She is known for being commercial and pragmatic in finding ways to help her clients and their partners achieve outcomes which are beneficial for both parties

more less

"has tremendous capacity to manage large and complex transactions, to distil the key risks, and to identify commercially sensible, pragmatic solutions"

Chambers UK

Relevant experience

  • Roslin Biomed (the “Dolly the Sheep” company) through its lifecycle and on its acquisition by Geron Corp.
  • NuCana BioMed on the in-licensing and acquisition of ProTides technology from Morvus and on its subsequent agreements for pre-clinical and clinical development of NuCana’s proprietary oncology products, including Acelarin.
  • Evexar Medical on the manufacturing and supply arrangements for its premium, single use, self-illuminated medical devices and on the supply arrangements for human tissue scaffold products
  • Consilient Health Limited on the distribution arrangements for Rewisca®.
  • Advising on the establishment and operation of the Stratified Medicine Scotland Innovation Centre, a collaborative venture between 4 universities, 4 health boards and 2 industrial partners, including drafting the consortium agreement, and negotiating agreements with suppliers of bioinformatics equipment/ next generation sequencing technology.
  • UCL Business on an investment of $20m by now MeiraGTx into Athena Vision, a spin out company established to develop gene therapy products for ocular conditions, including negotiating and advising UCLB on a complex collaboration, development and licence agreement with Meira.
  • Advising on the complex contractual, IP and revenue sharing arrangements for BloodPharma, a large multi-party research collaboration funded by Wellcome Trust, for the use of stem cells in the manufacture of red blood cells.
  • Glasgow University on many complex IP licensing arrangements over 18 years, including the licensing of vaccines to Wyeth and licensing genetically engineered seed strains to Bayer.
  • Dundee University on the arrangements for a large phase IV clinical trial conducted through the Scottish Primary Care Network for a global pharmaceutical company.
  • Yantai Jereh, a Chinese oil and gas company, on the in-licensing of various products and technologies from Plexus Plc for development and commercialisation in various Asian markets.
more less


1995 - Law, Dip LP. University of Glasgow, Glasgow

1994 - Law, LLB (Hons), University of Glasgow, Glasgow

Dual Qualified in Scots and English Law

more less


Show only
Our ehealth cap­ab­il­it­ies
Con­tract form­a­tion: so long postal ac­cept­ance?
As part of its work on the re­form of con­tract law in Scot­land, the Scot­tish Law Com­mis­sion (the “SLC”) has launched a con­sulta­tion seek­ing views on a work­ing draft of the Con­tract (Form­a­tion) (Scot­land) Bill (the “Bill”) which will mod­ern­ise and co­di­fy the.
Hos­pit­al­ity Mat­ters - Au­tumn 2014
Cur­rent top­ics in the hotel in­dustry
Su­preme Court rules again on in­ter­pret­a­tion of con­tracts: busi­ness...
In Wood v Cap­ita In­sur­ance Ser­vices Lim­ited [2017] UK­SC 24, the Su­preme Court has sought to re­con­cile the ap­proach to con­trac­tu­al con­struc­tion and in­ter­pret­a­tion ad­op­ted by the Su­preme Court in Rainy Sky v Kook­min Bank [2011] UK­SC 50 and Arnold v Brit­ton [2015].
The An­ti­dote - Spring 2014
Tak­ing a look at "pharm­er­ging" mar­kets and the re­sur­gence...
ICO draft guid­ance on con­sent un­der the GDPR pub­lished
The In­form­a­tion Com­mis­sion­er’s Of­fice (“ICO”) has opened for con­sulta­tion its draft guid­ance on con­sent un­der the Gen­er­al Data Pro­tec­tion Reg­u­la­tion (“GDPR”). The ICO is ac­cept­ing re­sponses un­til 31 March 2017.
Ex­press your­self: the Court of Ap­peal re­af­firms the po­s­i­tion that...
In the re­cent case of Ir­ish Bank Res­ol­u­tion Corp Ltd (In Spe­cial Li­quid­a­tion) v Cam­den Mar­ket Hold­ings Corp [2017] EW­CA Civ 7, the Court of Ap­peal once again con­sidered the test for terms be­ing im­plied in­to a con­tract.
Can pharma keep up with the chal­lenges of di­git­al health­care?
Please click here to read the full art­icle. Pharma com­pan­ies are be­gin­ning now to fo­cus on har­ness­ing ad­vances in di­git­al tech­no­lo­gies in their busi­nesses, from min­ing ge­n­om­ic data to identi­fy new drug tar­gets, to es­tab­lish­ing the most ap­pro­pri­ate pa­tients.
Third party rights Bill in­tro­duced in Scot­land
Fur­ther to our re­cent Law-Now, the Con­tract (Third Party Rights) (Scot­land) Bill (“the Bill”) is now mak­ing its way through the Scot­tish Par­lia­ment. The Bill, which the Scot­tish Gov­ern­ment is in­tro­du­cing with the in­ten­tion of mak­ing the law more flex­ible, up-to-date.
In­vest­ig­at­ory Powers Bill be­comes law
The In­vest­ig­at­ory Powers Act 2016 (the “Act”) has re­cently re­ceived Roy­al As­sent and be­come law. Re­pla­cing the Reg­u­la­tion of In­vest­ig­at­ory Powers Act 2000, the Act de­tails the powers the po­lice, se­cur­ity and in­tel­li­gence agen­cies hold which al­low them to col­lect.
Ac­cept­ance or counter-of­fer?
In Car­oline Gibbs v Lakeside De­vel­op­ments Ltd [2016] EWHC 2203, the High Court con­sidered wheth­er an email and at­tach­ment con­sti­tuted ac­cept­ance or counter-of­fer. As this is an Eng­lish de­cision, it is not tech­nic­ally bind­ing in Scot­land but it is highly per­suas­ive.
No­tice pro­vi­sions – take note!
The Court of Ses­sion has re­cently il­lus­trated the im­port­ance of strictly com­ply­ing with no­tice clauses. In Hoe In­ter­na­tion­al Lim­ited v Martha An­der­sen and Sir James Ayk­royd [2016] CSOH 33, the Court con­firmed that com­pli­ance with the terms of man­dat­ory no­tice.
Com­mer­cial Con­tracts Bul­let­in Septem­ber 2016
In this is­sue, we have con­sidered sig­ni­fic­ant and re­cent court de­cisions which are likely to af­fect the way you do busi­ness. We be­lieve these de­cisions could have an im­pact on the way that you, your cus­tom­ers, your sup­pli­ers and your com­pet­it­ors enter in­to.
Third party rights in Scot­land (up­date)
In our re­cent Law-Now, we ex­plained that the Scot­tish Law Com­mis­sion (SLC) has pub­lished a Re­port and draft Con­tract (Third Party Rights) (Scot­land) Bill with pro­pos­als for re­form of the Scots law of third party rights.
Uni­versity ordered to dis­close clin­ic­al tri­al data to a third party
In Queen Mary Uni­versity of Lon­don v In­form­a­tion Com­mis­sion­er EA/2015/0269, the First-Tier Tribunal held that an­onymised clin­ic­al tri­al data is not ex­empt from dis­clos­ure un­der The Free­dom of In­form­a­tion Act 2000 (FOIA).
Uni­versity ordered to dis­close clin­ic­al tri­al data to a third party
In Queen Mary Uni­versity of Lon­don v In­form­a­tion Com­mis­sion­er EA/2015/0269, the First-Tier Tribunal held that an­onymised clin­ic­al tri­al data is not ex­empt from dis­clos­ure un­der The Free­dom of In­form­a­tion Act 2000 (FOIA).
EU Com­mis­sion re­leases draft Pri­vacy Code of Con­duct for mHealth apps
The European Com­mis­sion has draf­ted a code of con­duct on pri­vacy for mo­bile health (mHealth) apps (the “Code”). The Code has been sub­mit­ted to the Art­icle 29 Data Pro­tec­tion Work­ing Group for ap­prov­al.
MHRA is­sues up­dated guid­ance on ehealth stand-alone soft­ware (in­clud­ing...
The Medi­cines and Health­care products Reg­u­lat­ory Agency (“MHRA”) has up­dated its guid­ance on stand-alone soft­ware in­clud­ing apps (the “Up­dated Guid­ance”). The Up­dated Guid­ance sets out the MHRA’s in­ter­pret­a­tion of the Med­ic­al Devices Dir­ect­ive (93/42/EEC) and.